Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
Loveman E, Cooper K, Bryant J, Colquitt JL, Frampton GK, Clegg A
Record ID 32011000773
English
Authors' recommendations:
Report identifies limited new information on the clinical effectiveness of dasatinib, nilotinib and high-dose imatinib for the treatment of people with chronic myeloid leukaemia (CML) who are resistant to standard-dose imatinib, but suggests that the interventions can lead to improvements in haematological and cytogenetic responses in people with imatinib-resistant CML.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2339
Year Published:
2012
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Benzamides
- Confidence Intervals
- Cost-Benefit Analysis
- Dasatinib
- Disease Progression
- Drug Resistance
- Drug Therapy, Combination
- Imatinib Mesylate
- Kaplan-Meier Estimate
- Models, Economic
- Quality-Adjusted Life Years
- Treatment Outcome
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Thiazoles
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2012 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.